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Folate deficiency has been associated with
neural tube defects, cardiovascular disease, and
anaemia [1, 2]. More recently, it has been hypoth-
esized that folate may modulate cancer risk [3–7],
notably risk of cervix and colorectal cancer, and
less well studied breast cancer and a rapidly grow-
ing number of other cancer sites such as lung, pan-
creas, stomach, oesophagus, leukaemia, skin, and
endometrium [8–13]. 
Mechanisms 
Two possible mechanisms by which low folate
may increase cancer risk are likely. First, in medi-
ating the transfer of one-carbon moieties, folate is
critical for the synthesis of S-adenosylmethionine
(SAM), an important compound for DNA methyl-
ation. DNA methylation is an epigenetic deter-
minant in gene expression, DNA stability, and mu-
tagenesis. Second, folate is important for normal
DNA synthesis and repair. Consequently, folate
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deficiency may lead to an imbalance in DNA
precursors, misincorporation of uridylate for
thymidylate in DNA synthesis, and chromosome
breakage [6, 7, 14–18].
Interactions between nutrients
Epidemiological findings suggest that subjects
who consume high amounts of alcohol, with a low
methionine and low folate diets may be at higher
risk for colon cancer than those consuming small
amounts of alcohol, with a diet high in folate and
methionine (see below). SAM is synthesised from
methionine which as well as being present in the
diet is synthesised by the transmethylation of ho-
mocysteine by methyltetrahydrofolate. Thus defi-
ciency of folate and/or methionine can lead to 
a decrease of SAM and subsequently to DNA 
hypomethylation. Alcohol may decrease DNA
methylation by interfering with folate absorption,
metabolism and excretion and/or through the an-
tagonistic action of its related metabolite acetalde-
hyde on methionine synthetase [19–22]. 
Gene-nutrition interactions
The possible involvement of a number of en-
zymic reactions involved in folate metabolism and
folate-mediated carcinogenesis has recently been
summarized by Kim [16]. Methylenetetrahydrofo-
late reductase (MTHFR) catalyses the biologically
irreversible reduction of 5,10-methylenetetra-
hydrofolate (5,10-methyleneTHF) to 5 methyl-
tetrahydrofolate (5-methylTHF). 5-methylTHF
provides the methyl group for de novo methionine
synthesis and indirectly for DNA methylation,
whereas 5,10-methyleneTHF is required for the
conversion of deoxyuridylate to thymidylate
needed for DNA synthesis. A common mutation
(677C→T, alanine→valine) has been detected in the
MTHFR gene. This mutation leads to thermola-
bility and slightly reduced activity of MTHFR, re-
sulting in lower levels of 5-methylTHF [23] and
higher levels of 5,10-methyleneTHF for thymidi-
late and DNA synthesis, etc. Some evidence exists
for an inverse association between MTHFR poly-
morphism and colorectal neoplasia. In agreement
with this hypothesis, in three (nested) case-control
studies [24–26] individuals with the homozygous
mutant MTHFR genotype (677TT) had a
40–50% reduction in colorectal cancer risk com-
pared with those with the heterozygous (677CT)
or normal (677CC) genotype. But this reduced risk
was only observed in those subjects with adequate
folate status. In individuals with inadequate folate
status, or with high alcohol consumption, the risk
reduction conferred by the MTHFR 677TT
genotype was abolished, suggesting possible gene-
nutrition interactions between folate status, alco-
hol intake, and the MTHFR 677 genotype in col-
orectal carcinogenesis (see below) [16]. Further-
more, in the case-control study by Levine et al. [27]
as well as in other studies (see below), compared
with those with at least one wild-type allele, TT
homozygotes in the lowest quartiles of RBC or
plasma folate showed an approximate doubling 
of adenoma risk, whereas adenoma risk in TT 
homozygotes in the highest folate quartile was 
decreased by 20% (RBC folate) or 50% (plasma 
folate). Thus, when folate intake is adequate, those
with MTHFR 677TT genotype may have a re-
duced risk because of adequate provision of methyl
donors. This would enhance DNA synthesis af-
fected by inhibition of the 5-methyltetrahydrofo-
late pathway due to diminished MTHFR enzyme
activity, and result in a decreased DNA damage.
However, when folate intake is low, both impaired
DNA methylation and DNA synthesis/repair may
become the primary mechanism of carcinogenesis
in those who have the variant MTHFR genotype
[28]. Accordingly, for paediatric leukaemia it is
hypothesized that in individuals with the MTHFR
677TT genotype decreased risk should be more
pronounced in subgroups of leukaemia character-
ized by chromosomal translocations [29]. Thus,
polymorphism is another means to show the folate
metabolism’s involvement in carcinogenesis. A
second common polymorphism of MTHFR in-
volves an A→C substitution at nucleotide 1298,
which causes glu→ala substitution in the MTHFR
protein [16]. According to Hanson et al. [30], this
mutation results in a small decrease in MTHFR
activity but no increased thermolability and no in-
teraction with plasma folate is observed. Further,
a recent study showed normal fasting total homo-
cysteine levels in subjects homozygous for this
polymorphism [30]. In a recent study a decrease in
risk of acute lymphatic leukaemia was observed in
individuals with the MTHFR 677TT genotype as
well as with the MTHFR 1298 CC genotype. In
addition double heterozygotes (677CT/1298AC)
showed a non-significant decreased risk of devel-
oping acute lymphocytic leukaemia compared
with 677CC/1298AA individuals [16, 31]. Con-
versely, in the case-control study by Song et al. [28]
the 1298CC genotype was associated with elevated
risk of oesophageal squamous cell carcinoma com-
pared with the 1298AA genotype. The same was
true for the 677TT compared with the 677CC
genotype. Moreover, in the study by Chen et al.
[32] a newly identified polymorphism (asp919gly)
of the methionine synthase gene revealed a non-
significant decrease in risk for colorectal adenomas
(OR 0.66; 95% CI 0.26–1.70). 
Epidemiological evidence
A number of epidemiological study designs are
available, and this has to be born in mind when as-
sessing results of such studies. Of these, case-con-
trol studies are of shorter duration and less expen-
sive to perform than cohort studies, but resulting
risk estimates may be distorted by selection and re-
call bias. Cohort studies are less susceptible to such
bias, since information is collected before a disease
develops. However, both types of studies are sus-
ceptible to confounding. When the results of case-
control and cohort studies are repeatedly consis-
tent, the case for causal links is strengthened. On
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the other hand, known and unknown confounding
is avoided in randomised, placebo-controlled, in-
tervention trials whereby subjects are allocated at
random to either active treatment or placebo.
Thus intervention trials may produce strong con-
clusions, but they are limited by the fact that they
can often only be interpreted for a particular study
population, and findings are valid only for the par-
ticular dose of a substance provided during the
trial, the duration of the trial, and the combina-
tions of agents used in a particular study [2]. The
epidemiologic evidence of a relationship between
folate status and cancer presented below will be
limited to cancer of the cervix, colon/rectum and
of the breast, the best studied cancer sites. Evi-
dence in relation to precursor lesions, such as ade-
nomatous polyps and cervical intraepithelial neo-
plasia is presented for better understanding and is
not tabulated.
Methods
All case-control, cohort, and intervention trials in hu-
mans reported in English, French, or German on folate
(intake or blood levels) in relation to the risk of colorec-
tal, breast, and cervix cancer were considered. We ex-
cluded studies of other cancer sites and overall cancer.
Four reviews [3, 5, 6, 33] were used as the basis of the bib-
liographic search. Further studies were found in the
MEDLINE® database, or they were referenced in the
identified studies. The process of cross-referencing was
continued until no new studies were found.
Among 32 epidemiological studies, we identified 10
case-control and 8 nested case-control or cohort studies
that reported on the relationship between intake or blood
levels of folate and colorectal cancer, 5 case-control and 3
nested case-control or cohort studies that reported on the
association with pre- and/or postmenopausal breast can-
cer, and 5 case-control and 1 nested case-control studies
that reported on the relationship between folate and inva-
sive cervical cancer. The methods and results of these sur-
veys are presented in Tables 1 to 3. 
Studies were summarized by type of design, year pub-
lished, number of cancer cases, exposure measurement, rel-
ative risk (RR) with 95% confidence intervals or p-values,
potential confounders controlled for by matching or in
analyses, and population/country. The presented RR were
those for the cancer rate in the highest intake or blood level
of folate divided by the rate of the lowest. In case-control
studies, the odds ratio was used to estimate the relative risk.
Studies comparing only mean values of cases and controls
but not estimating relative risks or odds ratios were ex-
cluded from the analysis. Only the newest results of a co-
hort or a case-control study were considered. No inter-
vention studies with colorectal, breast or invasive cervix
cancer as endpoints were found. Due to the limited num-
ber of studies available, small studies were also included in
the analysis, and no attempt was made to exclude studies
for the methods that were used. Due to the heterogeneity
of study design, exposure measurement and analysis, no
overall summary estimate of effect was attempted.
For better understanding, evidence in relation to the
precursor lesions, adenomatous polyps, and cervical in-
traepithelial neoplasia was added, but it was not tabulated
and no attempt of completeness was made. Other bio-
markers of cancer risk were not considered.
Results
Folate and colorectal neoplasia 
Colorectal carcinogenesis is a multistage
process comprising alterations in DNA methyla-
tion, hyperproliferation, adenoma formation, and
malignant transformation. Adenomatous polyps
(about two-thirds of all polyps) are considered pre-
cursors of colorectal cancer. International differ-
ences, migrant data, and recent rapid changes in
incidence rates in several countries indicate that
colon cancer is dependent on environmental
changes. Colorectal cancer is also known to occur
more frequently in certain families, in patients
with ulcerative colitis, or rare genetic syndromes.
It has been suggested that dietary constituents such
as vegetables, red and processed meat, alcohol,
etc., physical activity, aspirin, and smoking may act
as risk or protective factors [34–38]. 
Folate and adenomatous polyps 
Four of eight (nested) case-control studies [19,
32, 37–42] found a significant inverse association
between dietary [19, 38, 42] or blood folate [39]
and risk of adenomatous polyps. In one study a
non-significant decreased risk was observed espe-
cially in women [40]. Bird et al. [39] revealed in-
verse associations between red blood cells (RBC),
serum, and dietary folate (including supplements)
among men but not among women, the former two
associations being statistically significant. High di-
etary folate (including supplements), but not folate
from foods only, was inversely associated with risk
of colorectal adenoma in women (RR = 0.66; 95%
CI, 0.46–0.95) of the Nurses’ Health Study, and in
men (RR = 0.63; 95% CI, 0.41–0.98) of the Health
Professionals Follow-up Study [19]. The relative
risk of those with a high alcohol and low methio-
nine and folate intake compared with those with
low alcohol and high folate and methionine con-
sumption was 3.17 (95% CI, 1.69–5.95) (men and
women combined). The Nurses’ Health Study and
the Health Professionals Follow-up Study are both
large, well-designed, ongoing cohort studies
started in 1976 with 121,700 US registered nurses
and in 1986 with 51,529 US men working in the
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health sector, respectively. In the study by Baron
et al. [41] both dietary and supplemental folate in-
take were not significantly associated with the risk
of recurrence of large-bowel adenoma. Individuals
with folate intake below the median level and al-
cohol intake above the median level exhibited an
increased risk for adenoma compared with an in-
termediate group (one of the two variables at risk)
(OR = 1.85; 95% CI, 1.15–2.97). However, sub-
jects with folate intake above the median level and
alcohol intake below the median level and poten-
tially of low risk did not show lower risk compared
to the subjects within the intermediate group. 
Gene-nutrition interactions: The effect of the
677C→T polymorphism of MTHFR (see “mecha-
nisms”) on the risk of colorectal adenomas was
investigated within the Minnesota CPRU case-
control study [37]. Even though overall individuals
homozygous for the thermolabile mutation (TT
genotype) were at decreased risk for adenoma
compared with those with the wild type CC geno-
type (OR = 0.8; 95% CI, 0.6–1.3), individuals with
the TT genotype and with folate intake in the low-
est tertile were at increased risk for adenomas com-
pared with those with the CC genotype with high
intake (OR = 1.5; 95% CI, 0.6–3.5). Conversely,
among individuals with a MTHFR TT genotype
and high folate intake, a slightly decreased risk was
observed (OR = 0.7; 95% CI, 0.3–1.3). In the al-
ready mentioned case-control study by Levine et
al. [27] the odds ratio for the 677TT genotype was
slightly increased, compared with the presence of
at least one wild-type allele; apart from that the re-
sults are comparable with the findings of the study
by Ulrich et al. [37]. In the Nurses’ Health study
[32] a non-significant direct association between
the risk of adenomas and the 677TT genotype (RR
= 1.35; 95% CI, 0.84–2.17) was observed. Further,
there was no significant interaction between this
polymorphism and intake of either folate, methio-
nine, or alcohol. In the same study [32] polymor-
phism (2756A→G; asp→gly) in the gene for me-
thionine synthase (MTR) was also not significantly
associated with risk of colorectal adenomas (RR =
0.66; 95% CI, 0.26–1.70). 
Folate and colorectal cancer
Ten case-control and eight nested case-control
or cohort studies have been reported [20, 24–26,
42–55]. Six case-control and six prospective stud-
ies found a statistically significant inverse associa-
tion between intake (dietary, supplements) or
blood levels of folate and colorectal cancer at least
in subgroups [20, 24, 25, 43, 44, 46, 48, 49, 51–53,
55]. The methods and the results of these studies
are described in table 1. The case-control study 
by Levi et al. [50] was the only one showing an in-
creased risk with high folate intake, but the results
were statistically not significant (OR = 1.54; 95%
CI, 0.8–3.1). Of the six studies showing no signif-
icant association, three were based on rather small
numbers of cancer cases [26, 42, 54]. In the Nurses’
Health Study [55], women who used supplements
for more than 15 years had a reduced risk for 
colon cancer (multivariate RR = 0.25; 95% CI,
0.13–0.51). Dietary folate plus supplements for
less than 15 years did not result in a significant risk
reduction. Strengths of this study include its
prospective design, repeated dietary assessments,
validation of folate intake, comprehensive data on
potential confounders, and high follow-up re-
sponse rate. But because it was an observational
rather then a randomised study, the results cannot
definitely be attributed to folate.
Alcohol and methionine intake and genotype
may modulate the observed association between fo-
late and colorectal cancer. In two prospective stud-
ies, the association of a statistically significant in-
crease in risk of colorectal cancer and lower folate
intake was only observed when this was combined
with higher alcohol and lower methionine/protein
intake [20, 51]. In the Women’s Health Study [53]
the risk of colorectal cancer was almost twice as
high in subjects with serum folate below the me-
dian and total alcohol above the median compared
with higher serum folate and lower alcohol con-
sumption (OR = 1.99; 95% CI, 0.92–4.29). The
non-significant results may be due to the fact that
mean alcohol intake in this cohort was relatively
low, so that it may not be the most appropriate for
a study of the interaction with alcohol.
Gene-nutrition interactions: A decreased risk of
colon cancer among men homozygous for the
677C→T polymorphism of MTHFR was reported
in the Physicians’ Health [24] and the Health Pro-
fessionals Follow-up Study [26]. The former study
is a prospective case-control study nested in the
Physicians’ Health Study, a randomised trial of as-
pirin and beta-carotene among 22071 healthy US
male physicians. These two studies also revealed
that this inverse association was absent in individ-
uals with a low dietary intake of folate (or a low
plasma folate level), and that low methionine intake
or high alcohol consumption appeared to weaken
the inverse association. Similarly, in a recent case-
control study by Slattery et al. [25] the lowest risk
was observed in the group with the MTHFR TT
genotype and high intake of folate (OR = 0.6; 95%
CI, 0.4–1.0). In the two large cohorts Health Pro-
fessionals and Physicians’ Health [51] polymor-
phism (2756A→G; asp→gly) in the methionine
synthase gene (MTR) was associated with a statis-
tically non-significant 50% decreased risk of colo-
rectal cancer, but was not correlated with plasma
levels of folate. Further evidence of the link be-
tween folate and gastrointestinal cancer stems from
the encouraging preliminary intervention trials in
humans on folate and colorectal neoplasia [5, 56].
In summary, epidemiological studies support
an inverse association between folate status and the
rate of colorectal adenomas and carcinomas.
Long-term supplement use seems to be of greater
benefit than dietary intake. The association be-
tween folate intake and colorectal neoplasia seems
to be modulated by dietary factors such as alcohol,
and methionine. Furthermore, in individuals with
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Study design folate measure no. of colorectal assoc. relative risk/odds adjusted/ country/
and reference cancer cases ratioa (95% CI) matched forc population
Case-control
Freudenheim et al. 1991 diet 428 colon NS  1.03 (0.56–1.89) A, D, L Western 
[43] 372 rectal cancer NS  0.69 (0.36–1.30) New York
↓  0.31 (0.16–0.59)
NS  0.50 (0.24–1.03)
Benito et al. 1991 diet 286 males and ↓ ptrend 0.61 ptrend <0.05 A-D Mallorca,
[44] females Spain
Meyer et al. 1993 diet colon NS trend OR 1.19
[45] 424 males and (0.91–1.56) A, D, G, I, K Western
females NS trend OR 0.89 Washington
(0.66–1.22) State
Ferraroni et al. 1994 diet 828 males and ↓  0.63 (0.44–0.91) A-E, J Northern
[46] females ↓  0.37 (0.24–0.57) Italy
Slattery et al. 1997 diet (folate, alco- colon NS 0.99 (0.68–1.43)e A, C, D, F, H, Kaiser
[47] hol, methionine) 1993 males and O-Q, Aspirin Permanent
females use excluded Center
White et al. 1997 supplements colon, 251 males ↓ ptrend 0.59 (0.34–1.01) A Seattle area
[48] 193 females ↓ 0.44 (0.24–0.80)
La Vecchia et al. 1997 diet 1953 males and ↓ ptrend 0.83 (0.6–1.1) A, B, D, E, Italy
[49] females 0.06 H, I, M
Boutron et al. 1996 diet 171 colorect. NS 1.0 (0.5–2.0) A, D Burgundy, 
[42] cancer France
Slattery et al. 1999 diet and MTHFR colon (↓) 0.6 (0.4–1.0)f A-D, F, H, I Kaiser
[25] genotype 1467 males Permanent
and females Medical
Care program
Levi 2000 [50] diet 223 males and NS 1.54 (0.8–3.1) A-I Vaud, 
females Switzerland
Nested case-control
Chen et al. 1996 diet and MTHFR 144 men NS 0.44 (0.13–1.55)d A Health
[26] genotype Professionals
Follow-up
Study
Glynn et al. 1996 diet + supplements colon 91 NS colon: 0.51 (0.20–1.31) D, H, V, W baseline
[51] rectum 53 NS rectum: 2.12 (0.43–10.54) ATBC trial
serum NS colon: 0.96 (0.40–2.30) heavy smokers
alcohol, protein + NS rectum: 2.94 (0.84–10.33) 50–69 years
dietary folate ↑ colon: 4.79 (1.36–16.93)i 
serum folate NS colon: 1.28 (0.34–4.88)
Ma et al. 1997 plasma 202 males NS 1.78 (0.93–3.42)b Physicians’
[24] and MTHFR ↓ 0.32 (0.15–0.68)g A Health Study
genotype
Ma et al. 1999 plasma 356 males ↓ 0.29 (0.12–0.73)g A US male
[52] and MTHFR NS 0.57 (0.24–1.38)h Health
genotype Professionals
and MTR NS 0.51 (0.14–1.90)j plus
genotype Physicians’
Health Study
Kato et al. 1999 serum 105 females ↓ 0.52 (0.27–0.97) A, G, H, J, New York
[53] total intake NS 0.88 (0.46–1.69) R, S Women’s 
Health Study
Cohort
Lashner et al. 1997 supplements 4 males with colon NS 0.45 (0.05–3.80) unadjusted Chicago
[54] folic acid 1 mg or cancer and vs. no dysplasia
multivitamin ulcerative colitis
(0.4 mg)
Giovannucci et al. 1995 diet (folate, colon ↑ 3.30 (1.58–6.88)e A, C, D, F, US male
[20] alcohol, methi- 205 males H, N-Q, Health 
onine) Aspirin use Professionals
excluded
Giovannucci et al. 1998 diet + <15 y. suppl. colon NS 0.82 (0.56–1.20) A, C, F-H, US Nurses’
[55] multivitamin suppl. 442 women ↓ ≥15 years: 0.25 J, O, T, U Health Study
(0.13–0.51)
Table 1
Folate and risk of
colorectal cancer.
MTHFR polymorphisms and adequate folate in-
take a decreased risk of colorectal cancer has been
observed. However, no inverse association was ob-
served in those with a diet inadequate in folate,
high in alcohol, or low in methionine. Finally, the
corresponding findings for colorectal adenomas
are conflicting. The results of a recent cross-sec-
tional study [57] showing that in smokers, high fo-
late status may confer increased or decreased risk
for high risk adenoma, depending on the MTHFR
genotype, may explain some of the inconsistent
data. Animal trials have provided considerable sup-
port for the epidemiological findings [58]. Animal
studies have also shown a dose-dependent protec-
tive effect of modest levels of dietary folate sup-
plementation up to few times the dietary require-
ments did not convey further benefits; in fact, there
was a nonsignificant trend towards increased colo-
rectal tumorigenesis in rats fed a supraphysiolog-
ical dose of folate [59, 60]. In addition, the timing
of folic acid supplementation may be important. In
a mouse model for colon cancer, folic acid supple-
mentation given before microscopic neoplastic
foci were established suppressed the development
of intestinal adenoma, while supplementation
given after the establishment of neoplastic foci ap-
peared to have an opposite effect on ileal polyps
[61, 62]. In addition, Leu et al. found that folate
deficiency reduced the development of tumori-
genesis right through to colorectal cancer in
azoxymethane-treated rats. The authors consid-
ered it as likely that the lower tissue folate con-
centrations of folate deficient animals may have
inhibited the promotion and/or progression of
tumorigenesis [63].
Folate and breast cancer 
Several risk factors for breast cancer have
been established, most of which relate to repro-
ductive events. An increase in a reproductive life-
time that includes later and fewer births results in
an increase in risk, i.e. endogenous hormones,
particularly oestrogens have been implicated as
underlying determinants. A family history of
breast cancer and inheritance of mutations in spe-
cific genes increase the risk. The same is true for
ionising radiation. A number of dietary factors
have been hypothesized as risk or protective fac-
tors (alcohol, body weight, vegetables, fruits, etc.)
but convincing evidence is lacking for all of them
[35]. 
The methods and the results of epidemiolog-
ical studies on the relationship between folate and
breast cancer are summarised in table 2. Numbers
of breast cancer cases varied considerably between
studies, i.e. from several hundreds [64–67, 69] to
several thousands [68, 70, 71]. Of five case-control
studies [64–68], all but one [66] found a signifi-
cantly decreased risk of pre- and postmenopausal
breast cancer with a higher intake of folate. In two
of these studies, the OR were no longer significant
when adjusted for vegetable intake [65, 67]. On the
other hand in the study by Ronco et al. [67] the in-
verse association remained statistically significant
when vegetable intake was adjusted for dietary fo-
late. Furthermore, in the survey by Freudenheim
et al. [65] the use of folic acid supplements was not
associated with reduced risk in premenopausal
women with breast cancer. Similarly, in the study
by Potischman et al. [66]neither dietary folate (OR
= 0.89; 95% CI, 0.7–1.2) nor folate from food plus
supplements were associated with early stage
breast cancer. Considering prospective studies, a
nested case-control study [69] showed no associa-
tion between serum folate levels and the incidence
of breast cancer. Also in the very large, well-de-
signed cohort study with 3483 breast cancer cases
by Zhang et al. [70] total folate intake was not as-
sociated with overall risk of breast cancer. How-
ever, higher total folate intake or multivitamin use
was associated with a lower risk of breast cancer
among women of the Nurses’ Health Study who
regularly consumed alcohol. These data suggest
that alcohol consumption modified the association
of folate intake with breast cancer risk in a similar
manner to the interaction between folate and al-
cohol observed for colon cancer. Similarly, the re-
sults of a large case-cohort analysis by Rohan et al.
[71] suggest that dietary folate consumption might
be associated with reduced risk of breast cancer at
relatively high levels of alcohol intake, particularly
in postmenopausal women. Also the case-control
study by Negri et al. [68] based on 2569 breast can-
cer cases confirms that high folate intake may have
a favourable effect in women consuming two or
more alcoholic beverages per day. Other studies of
folate and breast cancer have not evaluated risk in
relation to levels of alcohol [64–67]. With respect
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a high vs. low 
↓ statistically significant inverse association. (↓), higher 95% CI = 1.↑, statistically significant direct association. 
NS, statistically non-significant association
b low vs. high
c A, age; B, sex; C, weight; D, total energy intake; E, education; F, smoking; G, alcohol; H, physical activity; I, fiber; J, family history of 
colorectal cancer; K, interviewer; L, neighborhood; M, center; N, history of polyps; O, red meat consumption; P, multivitamin use; 
Q, history of endoscopy; R, menopausal status; S, prior occult blood testing; T, aspirin; U, methionine; V, vitamin A; W, starch
d high folate intake-MTHFR TT vs. low folate intake-MTHFR CC or CT
e high alcohol-low folate-low methionine vs. low alcohol-high folate-high methionine
f high folate intake-MTHFR TT vs. low folate intake-MTHFR CC 
g high plasma folate-MTHFR TT vs. high plasma folate-MTHFR CC or CT
h low plasma folate-MTHFR TT vs. high plasma folate-MTHFR CC or CT
i high alcohol, low folate, low protein vs. low alcohol, high folate, high protein
j high plasma folate-MTR gly/gly vs. high plasma folate-MTR gly/asp or asp/asp
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to the 677C→T polymorphism of MTHFR it ap-
pears to enhance the risk of breast cancer [72].
In summary, recent studies suggest an inverse
association between folate intake and breast can-
cer among women who regularly consume alcohol.
Folate and cervical intraepithelial neoplasia
and cervical cancer
Invasive squamous cell carcinoma (95% of cer-
vical cancers) arises from precursor lesions of the
cervix known as cervical intraepithelial neoplasia
(CIN). CIN I represents very mild dysplasia with
a high rate of spontaneous regression, CIN II and
III, moderate to severe dysplasia, with a consider-
ably higher rate of progression to invasive cancer.
The main causal factor for cervix cancer is thought
to be sexually transmitted infectious agents, almost
certainly the human papillomaviruses (HPVs).
During infection HPV must be integrated into the
host DNA, which occurs preferentially at fragile
sites. Low tissue folate levels increase the fre-
quency of such fragile sites on DNA. Less well es-
tablished risk factors for cervix cancer are smoking
and use of oral contraceptives (OC) [33–35]. 
Folate and cervical intraepithelial neoplasia
As long ago as 1982 a small trial, in which 47
OC users randomly received 10 mg of either folic
acid or ascorbic acid/day for 3 months, revealed
that treatment with folic acid was significantly as-
sociated with CIN regression [73]. Conversely, two
more recent folic acid intervention trials reported
negative results. In one of these, 235 women with
CIN I or CIN II lesions randomly received either
10 mg folic acid or vitamin C daily for 6 months.
Although RBC folate significantly increased in the
intervention group, no significant differences in
rates of either CIN regression or progression were
observed [74]. In the other trial [75], 331 patients
with koliocytic atypia, CIN I, or CIN II received 5
mg folic acid or placebo randomly. Regression was
of borderline statistical significance after 3 months,
and no difference was seen between the groups
after 6 months of treatment.
Folate and invasive cervical cancer
None of three case-control studies on diet and
invasive cervical cancer showed a dose-response
association with folate intake [76–78]. Similarly
Study design menopausal folate no. of association relative risk/odds adjusted/ country/
and reference status measure cases ratioa (95% CI) matched forb population
Case-control
Graham et al. 1991 post dietary 439 ↓ ptrend 0.03 0.70 (0.48–1.02) A-H Erie, Niagara
[64] intake Counties
Freudenheim et al. 1996 pre dietary 297 ↓ 0.50 (0.31–0.82) A-F, H, I Erie, Niagara
[65] intake NS 0.76 (0.43–1.37) A-F, H, I, ZZ Counties
supplements NS 0.97 (0.67–1.42) A-F, H, J
Potischman et al. 1999 pre diet plus 568 NS 1.11 (0.8–1.5) B, C, K-P 3 US centers
[66] supplements
Ronco et al. 1999 pre and post dietary intake 400 ↓ ptrend 0.01 0.70 (0.46–1.07) A, D,E, G-I, Q,Uruguay 
[67] NS 0.98 (0.60–1.59) R, S plus ZZ
Negri et al. 2000 pre and post diet 2569 ↓ all: 0.73 (0.60–0.88) A, B, G, I, L, S six Italian 
[68] ↓ pre: 0.57 (0.41–0.78) areas
↓ post: 0.79 (0.62–0.99)
↓ ≥25 g alcohol/d: 0.49 
(0.32–0.74)
Nested case-control
Wu et al. 1999 pre and post serum 195 NS 1974: 1.08 (0.50–2.37) A, M, S, T Washington 
[69] NS 1989: 0.79 (0.33–1.90) County
Cohort
Zhang et al. 1999 pre and post diet plus 3483 NS all: 0.93 (0.83–1.03) A, C-II (N), Nurses’ 
[70] suppl. ↓ ≥ 15 g alcohol: 0.56 S, U-Y Health Study
(0.41–0.79)
Multi- ↓ current vs. never + 
vitamins ≥ 15 g alcohol: 0.74 
(0.59–0.93)
Rohan et al. 2000 pre and post diet 1469 NS all: 0.99 (0.79–1.25) A, D, E, G, I, Canada
[71] ↓ > 14 g alcohol: 0.34 L (N), S, Z
(0.18–0.61)
↓ post + >14 g alcohol: 
0.28 (0.14–0.55) 
a high vs. low
↓ statistically significant inverse association. NS, statistically non-significant association.
b A, age; B, education; C, age at first pregnancy; D, age at menarche; E, relative with breast cancer; F, benign breast disease; G, number 
of pregnancies; H, body weight; I, total energy intake; J, dietary intake of folate; K, age at diagnosis; L, study site; M, ethnicity, race;
N, alcohol; O, oral contraceptive use; P, smoking; Q, residence; R, urban/rural; S, menopausal state; T, date of blood donation; 
U, length of follow-up; V, weight change; W, age at menopause; X, hormone replacement therapy; Y, beta carotene; 
Z, practice of breast examination; ZZ, total vegetable intake 
Table 2
Folate and risk of
breast cancer.
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Potischman et al. [80]observed no association be-
tween folate serum levels and invasive cervical can-
cer in the case-control study in four Latin Ameri-
can countries. In the small nested case-control
study by Alberg et al. [79] adjusted odds ratios
(OR), based on only 39 cases, were 1.0; 0.62; and
0.6 (95% CI, 0.19–1.88) for the low to high tertiles
of serum folate concentrations, respectively, an in-
verse trend which was not statistically significant.
The methods and the results of these studies are
described in table 3. Recently, in a multicenter,
community-based case-control study in the US
[81] low serum and red cell folate were each mod-
erately, but non-significantly, associated with in-
creased invasive cervical cancer risk. In addition, a
strong significant positive association between
serum homocysteine and cervical cancer was ob-
served, providing evidence that the moderate fo-
late association was real [82].
In summary, the effect of folate on carcino-
genesis in the cervix remains uncertain. Two trials
showed no significant effect of folic acid on the
rates of cervical intraepithelial neoplasia regres-
sion or progression. An inverse association be-
tween folate and later stages of carcinogenesis is
not suggested by the few (nested) case-control
studies on invasive cervical cancer.
Discussion and conclusions
With the important exception of cervix cancer,
only recently it has been hypothesized that folate
may modulate cancer risk. In summary, epidemio-
logical studies support an inverse association be-
tween folate status and the rate of colorectal ade-
nomas and carcinomas. Folate taken long term as
supplements seems to be of greater benefit than
higher intake in food. The corresponding findings
for colorectal adenomas are conflicting. Moreover,
recent studies suggest an inverse association be-
tween folate intake and breast cancer among
women who regularly consume larger amounts of
alcohol. On the contrary, the effect of folate on car-
cinogenesis in the cervix remains uncertain. Two
prevention trials showed no significant effect of
folic acid on rates of cervical intraepithelial neo-
plasia regression or progression. An inverse asso-
ciation between folate and later stages of carcino-
genesis is not suggested by the few (nested) case-
control studies on invasive cervical cancer.
Some of the conflicting results may be due to
the fact that folate deficiency has not been assessed
accurately. The epidemiological studies have re-
lied on either dietary folate or blood folate con-
centrations as estimates of folate status. It is for ex-
ample recognized that food folate composition
data provide inaccurate estimations of folate intake
and that there is substantial variation within and
across methods of the analysis of serum and whole-
blood folate [4]. When measurement errors are in-
Study design folate measure number association relative risk/odds adjusted/ country/
and reference of cases ratioa (95% CI) matched forc population
Case-control
Verreault et al. 1989 diet 189 NS 0.8 (0.3–1.7) A-G, K Seattle, USA
[76] supplements NS not reported
Ziegler et al. 1990 diet 218 NS 0.85 (0.5–1.5)b A-D, F, G, M white women,
[77] supplements not reported RR = 1.03 USA
Herrero et al. 1991 diet 748 NS 0.95 (0.7–1.3) A, B, E, G-I, M 4 Latin Ameri-
[78] can countries
Potischman et al. 1991 serum 330 NS 1.05 (0.7–1.6) A, B, E, G-I 4 Latin Ameri-
[80] can countries
Weinstein et al. 2001 serum 183 A-E, G-J, M, O 5 US areas
[81] (microbiol.) NS 1.3 (0.8–2.9)b
radiobinding NS 1.6 (0.9–2.9)b
red cell 
(microbiol.) NS 1.2 (0.6–2.2)b
radiobinding NS 1.5 (0.8–2.7)b
Nested case-control
Alberg et al. 2000 serum 39 NS 0.60 (0.19–1.88) A, C-E, I, Washington
[79] J, L, N County, Mary-
land, USA
NS statistically non-significant association 
a high vs. low
b low vs. high
c A, age; B, sexual activity; C, smoking; D, oral or barrier contraceptive use; E, socioeconomic status, education, income; F, history of 
genital infection; G, time since last Pap smear or frequency of Pap smears; H, parity; I, HPV infection (HPV-16 and/or HPV-18); 
J, race, ethnicity; K, total energy; L, data of blood donation; M, study center, telephone exchange; N, time since last menstrual period;
O, age at first intercourse
Table 3
Folate and risk of
invasive cervical
cancer.
dependent of outcome their tendency is to bias re-
sults toward the null [55].
Also, it is not clear whether such measure-
ments accurately assess the concentration of folate
in the cells of cancer origin, which is likely to be
more critical [83]. Tissue-specific susceptibility to
folate deficiency has for example been shown in
smokers; buccal mucosal cells were low in folate
when systemic folate concentrations were normal
[84]. Furthermore, Meenan et al. [85] described
the lack of association between erythrocyte folate
levels and colonic biopsy specimens in healthy in-
dividuals, indicating the potential difficulty in pre-
dicting localized folate deficiency. In a subsequent
report [86], epithelial cell folate depletion oc-
curred in neoplastic but not in adjacent normal
colonic mucosa. Conversely, in patients with
polyps the folate content of colon biopsy samples
was significantly correlated with serum and red cell
folate concentrations [87]. 
Some of the negative results may also be due
to the fact that the association between folate and
cancer seems to be modulated by other dietary fac-
tors (e.g. alcohol, methionine), as well as genetic
polymorphisms, aspects which have not been taken
into account in many of the previous studies. Cau-
casian and Asian populations show frequency rates
of 677C→T polymorphism of MTHFR of about
12% for those who are homozygous, and up to
50% for those who are heterozygous [16]. In ad-
dition, polymorphism of a potentially wide range
of other enzymes involved in folate metabolism
may modulate cancer risk (see above).
Taking all the present evidence into account it
remains to be established whether folate itself is di-
rectly linked to the risk of cancer of various sites.
Importantly, the observed inverse associations be-
tween folate and cancer may be confounded by nu-
merous factors, especially by other potentially pro-
tective constituents in fruit and vegetables, an im-
portant dietary source of folate. Intervention stud-
ies can exclude such confounding. For colorectal
cancer at least four large, randomised, placebo-con-
trolled chemoprevention trials are ongoing in the
United States [3], but the optimal dose of folate, the
duration and stage of carcinogenesis, and the ap-
propriate (genetically predisposed) study group for
folate chemoprevention are not yet defined. Results
from animal trials suggest that folate supplementa-
tion might decrease or increase cancer risk de-
pending on dosage and timing. The emerging pic-
ture is one of complex interaction of multiple nu-
tritional and genetic factors whose fine balance can
be disturbed leading to important predisposition
for a range of common diseases such as neural tube
defects, vascular disease and now cancer.
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